BLE0 Stock Overview A biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
bluebird bio, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for bluebird bio Historical stock prices Current Share Price US$9.44 52 Week High US$33.60 52 Week Low US$5.80 Beta 0.75 1 Month Change 39.84% 3 Month Change 4.52% 1 Year Change -62.68% 3 Year Change -95.15% 5 Year Change n/a Change since IPO -97.14%
Recent News & Updates
New minor risk - Insider selling Dec 14 Bluebird Bio, Inc. Announces Updated Data from Patients with Beta-Thalassemia Who Require Regular Blood Transfusions Treated with Betibeglogene Autotemcel (Beti-Cel, Approved Commercially as ZYNTEGL) in Clinical Studies
Insufficient new directors Dec 01
New major risk - Negative shareholders equity Nov 15
Forecast to breakeven in 2026 Nov 15
bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Nov 05 See more updates
New minor risk - Insider selling Dec 14 Bluebird Bio, Inc. Announces Updated Data from Patients with Beta-Thalassemia Who Require Regular Blood Transfusions Treated with Betibeglogene Autotemcel (Beti-Cel, Approved Commercially as ZYNTEGL) in Clinical Studies
Insufficient new directors Dec 01
New major risk - Negative shareholders equity Nov 15
Forecast to breakeven in 2026 Nov 15
bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Nov 05
bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1) Oct 05
bluebird bio, Inc., Annual General Meeting, Nov 06, 2024 Sep 19
bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1) Aug 25 bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024
bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024 May 30 bluebird bio, Inc. announced delayed 10-Q filing May 17
Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy May 07 Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc Mar 29
bluebird bio, Inc. announced delayed annual 10-K filing Mar 27
bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million. Dec 21
New major risk - Shareholder dilution Dec 20 bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million. Dec 20
bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Dec 19
New major risk - Revenue and earnings growth Dec 18 Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels
Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events Dec 09
Now 41% undervalued after recent price drop Dec 09
Bluebird Bio, Inc. Announces FDA Approval of LYFGENIA™? (Lovo-Ccel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events Dec 09
Now 24% undervalued Nov 10
Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.94 loss in 3Q 2022) Nov 08
New major risk - Revenue and earnings growth Nov 08
Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition Nov 03
bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 26
bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 25
New minor risk - Insider selling Aug 14
President recently sold €54k worth of stock Aug 12
Second quarter 2023 earnings released: US$0.67 loss per share (vs US$1.36 loss in 2Q 2022) Aug 09
bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events Jun 22
First quarter 2023 earnings released: EPS: US$0.21 (vs US$1.66 loss in 1Q 2022) May 10
Less than half of directors are independent Apr 24
Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021) Mar 30
Less than half of directors are independent Mar 22
Less than half of directors are independent Feb 09
bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer Jan 04
U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18 Dec 20
Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition Dec 13
An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million. Dec 02
Less than half of directors are independent Nov 16
Third quarter 2022 earnings released: US$0.94 loss per share (vs US$2.23 loss in 3Q 2021) Nov 09 bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022
bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD) Sep 17 bluebird bio, Inc. Announces Executive Changes
Treasurer recently sold €78k worth of stock Aug 25
bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions Aug 18
President recently sold €94k worth of stock Aug 10
Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021) Aug 07
bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022 Aug 06
bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy Jun 11
FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy Jun 10
Less than half of directors are independent Jun 01
bluebird bio, Inc., Annual General Meeting, Jun 22, 2022 May 03 Bluebird Bio, Inc. Announces Executive Changes
bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022 Mar 06 bluebird bio, Inc. announced delayed annual 10-K filing Mar 03
bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer Feb 05
CEO & Director recently sold €65k worth of stock Jan 20
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD) Jan 19
bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022 Jan 12
bluebird bio, Inc. Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program Dec 21
bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor Dec 19
bluebird bio, Inc. Announces Updated Results from its Phase 1/2 HGB-206 Study of Lovotibeglogene Autotemcel Gene Therapy Dec 13
New Data At ASH21, Published in Nejm Further Demonstrate Beti-Cel as A Potentially Curative One-Time Gene Therapy for ß-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Ti and Normal or Near-Normal Adult Hb Levels Dec 12
Bluebird Bio, Inc. Announces FDA Priority Review of Biologics License Application for Beti-Cel Gene Therapy for Patients with ß-Thalassemia Who Require Regular Red Blood Cell Transfusions Nov 24
Third quarter 2021 earnings released: US$3.16 loss per share (vs US$2.94 loss in 3Q 2020) Nov 06
Insufficient new directors Oct 04 Shareholder Returns BLE0 DE Biotechs DE Market 7D 0% -2.6% -2.0% 1Y -62.7% -13.2% 6.8%
See full shareholder returns
Return vs Market: BLE0 underperformed the German Market which returned 6.8% over the past year.
Price Volatility Is BLE0's price volatile compared to industry and market? BLE0 volatility BLE0 Average Weekly Movement 37.9% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: BLE0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BLE0's weekly volatility has increased from 24% to 38% over the past year.
About the Company bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.
Show more bluebird bio, Inc. Fundamentals Summary How do bluebird bio's earnings and revenue compare to its market cap? BLE0 fundamental statistics Market cap €71.63m Earnings (TTM ) -€281.64m Revenue (TTM ) €51.09m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BLE0 income statement (TTM ) Revenue US$53.12m Cost of Revenue US$78.78m Gross Profit -US$25.66m Other Expenses US$267.16m Earnings -US$292.82m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -30.12 Gross Margin -48.31% Net Profit Margin -551.25% Debt/Equity Ratio -1,394.4%
How did BLE0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 13:43 End of Day Share Price 2024/12/09 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources bluebird bio, Inc. is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jack Allen Baird Huidong Wang Barclays Zhiqiang Shu Berenberg
Show 31 more analysts 